Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29038231 | 0.82 | HIF1A (0.65) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL599748 | 0.80 | SLC7A5 (0.62) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL2779272 | 0.80 | SLC7A5 (0.62) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL29588290 | 0.80 | SLC7A5 (0.62) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL2310526 | 0.79 | SLC7A5 (0.83) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL7190053 | 0.79 | SLC7A5 (0.61) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL2496326 | 0.78 | SLC7A5 (0.65) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL28653399 | 0.78 | SLC7A5 (0.65) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL18645038 | 0.78 | HIF1A (0.73) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 | |
| SCHEMBL14233567 | 0.78 | SLC7A5 (0.69) | HIF1ACYP3A4ALOX15PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216492-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CV BIOMANUFACTURING, LLC | 2024-07-04 | — | — | US | claimed |
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2022232176-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | DNATRIX, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| US-11345730-B2 | Chimeric protein in the treatment of amyloidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-05-31 | — | — | US | claimed |
| EP-2806883-B1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNATRIX INC (US) | 2019-04-24 | — | — | EP | claimed |
| US-20180298071-A1 | Chimeric Protein in the Treatment of Amyloidosis | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) | 2018-10-18 | — | — | US | claimed |
| US-20160264637-A1 | CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIO- TECHNOLOGIES (FR) | 2016-09-15 | — | — | US | claimed |
| EP-3063277-A1 | CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS | Laboratoire Français du Fractionnement et des Biotechnologies (FR) | 2016-09-07 | — | — | EP | claimed |
| WO-2015063728-A1 | CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR) | 2015-05-07 | — | — | WO | claimed |
| US-12291552-B2 | Chimeric protein in the treatment of amyloidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-05-06 | — | — | US | disclosed |
| US-20240216492-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CV BIOMANUFACTURING, LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240156766-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240139137-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140213650-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013123026-A1 | RLIP76 AS A MEDICAL CHEMICAL COUNTERMEASURE | TERAPIO CORPORATION (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2012022634-A1 | CLASSIFICATION, DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-02-23 | — | — | WO | disclosed |
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010138920-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALOX15 3124/4885 |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALOX15 3124/4885 |
| US-20240156766-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALOX15 3124/4885 |
| US-20140213650-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | HIF1A 4130/4885CYP3A4 493/4885ALOX15 3372/4885 |
| US-20240139137-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | HIF1A 4130/4885CYP3A4 493/4885ALOX15 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.